Ryohei Katayama

发表

Image Based Estimation of Grasp Type using Deep Learning based on Correlation between Hand Shape and Object Shape

Koichi Ogawara, Ryohei Katayama, 2017 .

2A1-S05 Hand shape estimation based on Hu's invariant moment considering the mutual occlusion between hand and object using RGB-D Camera

Koichi Ogawara, Ryohei Katayama, 2015 .

Patient-derived models of acquired resistance can identify effective drug combinations for cancer

Sridhar Ramaswamy, Mari Mino-Kenudson, Ryohei Katayama, 2014, Science.

The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.

Makoto Nishio, Peter McNamara, Ryohei Katayama, 2014, Cancer discovery.

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer

Yasushi Okuno, Ryohei Katayama, Mitsugu Araki, 2017, Nature Communications.

Acquired resistance to crizotinib from a mutation in CD74-ROS1.

Mari Mino-Kenudson, Ryohei Katayama, Sidra Mahmood, 2013, The New England journal of medicine.

Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer.

Ryohei Katayama, Ryohei Katayama, 2017, Pharmacology & therapeutics.

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.

Shibing Deng, Hui Wang, Shinji Yamazaki, 2015, Cancer cell.

Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.

Ryohei Katayama, Naoya Fujita, Jie Qi, 2013, Cancer research.

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK

Ryohei Katayama, Cyril Benes, A. Iafrate, 2011, Proceedings of the National Academy of Sciences.